8,695,652 Shares in Century Therapeutics, Inc. $IPSC Purchased by Commodore Capital LP

Commodore Capital LP acquired a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,695,652 shares of the company’s stock, valued at approximately $19,652,000. Century Therapeutics makes up about 1.1% of Commodore Capital LP’s holdings, making the stock its 25th biggest holding.

Other large investors also recently bought and sold shares of the company. Prudential Financial Inc. acquired a new position in shares of Century Therapeutics in the 2nd quarter worth approximately $25,000. Bank of New York Mellon Corp acquired a new stake in shares of Century Therapeutics during the 1st quarter valued at approximately $29,000. Qube Research & Technologies Ltd acquired a new stake in shares of Century Therapeutics during the 2nd quarter valued at approximately $38,000. Quadrant Private Wealth Management LLC lifted its stake in Century Therapeutics by 31.0% during the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after purchasing an additional 4,736 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Century Therapeutics during the second quarter worth $51,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Stock Performance

Shares of NASDAQ:IPSC opened at $2.11 on Monday. The firm’s 50 day moving average is $2.26 and its two-hundred day moving average is $2.22. Century Therapeutics, Inc. has a 52 week low of $0.44 and a 52 week high of $3.04. The firm has a market capitalization of $380.54 million, a P/E ratio of -1.85 and a beta of 1.55.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. Analysts predict that Century Therapeutics, Inc. will post -0.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Mizuho initiated coverage on shares of Century Therapeutics in a research note on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price objective on the stock. HC Wainwright raised their target price on shares of Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Finally, Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.75.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.